Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
SUSVIMO for Age-Related Macular Degeneration
Recruiting3 awardsPhase 4
Pasadena, California
This trial will assess the response to treatment with SUSVIMO given every 24 weeks in patients with nAMD who have been previously treated with anti-VEGF agents. A substudy will evaluate the impact of SUSVIMO on corneal endothelial cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service